Takeda Partners with Sun Pharma and Cipla for Vonoprazan Commercialization in India

Japan's Takeda Pharmaceutical has granted Sun Pharmaceutical and Cipla the rights to commercialize Vonoprazan, a gastrointestinal drug, in India. Vonoprazan, sold as tablets under the brand name "Voltapraz," blocks a crucial step in stomach acid production, according to Sun Pharma's announcement on Friday. Cipla shared the agreement a day earlier.

Takeda has provided both companies with non-exclusive patent licensing rights for the drug, aimed at treating gastroesophageal reflux disease (GERD), which affects 5% to 28.5% of India's population.

Earlier this month, Torrent Pharmaceuticals also struck a deal with Takeda to market Vonoprazan in the Indian market, expanding the availability of this treatment for GERD patients.